Infectious Diseases News and Research

RSS

How stress fuels allergic skin inflammation

Researchers investigate the cellular and molecular mechanisms through which stress exacerbates immunoglobulin E cutaneous allergic inflammation.

9 Jan 2025

Gut microbes and the body work together to regulate fat metabolism

Beneficial gut microbes and the body work together to fine-tune fat metabolism and cholesterol levels, according to a new preclinical study by investigators from Weill Cornell Medicine and the Boyce Thompson Institute at Cornell University's Ithaca campus.

9 Jan 2025

Extreme weather impacts HIV prevention and treatment access

New challenges in HIV prevention and care are emerging due to climate change, according to a review published earlier this month in Current Opinions in Infectious Disease.

8 Jan 2025

AI-designed drug shows promise for inflammatory bowel disease

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico's Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).

8 Jan 2025

AI-based method predicts progression of autoimmune diseases

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that's characterized by mild symptoms or certain antibodies in the blood.

7 Jan 2025

Early results of doxy PEP rollout show mixed impact on STIs

As health care services begin offering doxycycline to prevent bacterial sexually transmitted infections (STIs), real-world evidence demonstrates that the postexposure strategy, called doxy PEP, is reducing the rate of syphilis and chlamydia, but has had little to no effect on gonorrhea and needs close monitoring for signals of antibiotic resistance.

6 Jan 2025

H5N1 bird flu spillover to horses, raises fears of new viral strains

Researchers report the first confirmed cases of H5N1 bird flu in horses, highlighting their role as potential reservoirs for viral reassortment. This groundbreaking study urges increased surveillance to prevent novel influenza epidemics.

5 Jan 2025

Human protein MxA restricts H5N1, but virus mutations raise alarms

Human MxA protein suppresses mammalian H5N1 virus replication, but emerging mutations may enable partial evasion, raising concerns for human transmission.

5 Jan 2025

Y chromosome’s unexpected impact on aging and disease in men

Loss of the Y chromosome (LOY) in men, a dynamic mutation linked to aging, impairs immune function and increases risks of cancer, Alzheimer’s, and cardiovascular diseases, making it a promising biomarker and therapeutic target.

5 Jan 2025

From ducks to detection: Revolutionizing surveillance in the fight against HPAI

Vaccination drastically reduces avian influenza outbreaks in ducks, but enhanced passive surveillance is crucial for timely and effective detection of the virus.

5 Jan 2025

Professor Alison Elliott honored with OBE for contributions to global health

Leading clinical researcher Professor Alison Elliott has been honoured with an OBE in the King's New Year Honours for services to medicine and global health.

3 Jan 2025

Scientists identify novel antibodies for fighting malaria

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published today in Science.

3 Jan 2025

Predicting H5N1 disease severity based on T cell responses

New research led by scientists at La Jolla Institute for Immunology (LJI) suggests that many people already have immune cells on "stand by" to fight the H5N1 virus, also known as highly pathogenic avian influenza.

2 Jan 2025

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers.

2 Jan 2025

Blood cells linked to long-lasting vaccine immunity

When children receive their second measles-mumps-rubella vaccine, around the time they start kindergarten, they gain protection against all three viruses for all or most of their lives.

2 Jan 2025

KFF Health News' 'What the Health?': Francis Collins on supporting NIH and finding common ground

This week, KFF Health News' "What the Health?" presents a conversation with Francis Collins, former National Institutes of Health director and White House science adviser.

2 Jan 2025

Public health experts outline critical steps in handling HPAI H5N1 spread

Highly pathogenic H5N1 avian influenza A virus (HPAI H5N1) remains a low risk to the general public, and public health experts in the United States believe that available treatments and vaccines, as well as those in development, are sufficient to prevent severe disease.

2 Jan 2025

AI-driven surveillance system to combat emerging infectious diseases

Researchers have come up with a new way to identify more infectious variants of viruses or bacteria that start spreading in humans - including those causing flu, COVID, whooping cough and tuberculosis.

2 Jan 2025

Skin explants reveal how Ebola virus moves through the body

Ebola is a deadly hemorrhagic disease caused by a virus that is endemic in parts of East-Central and West Africa. Most people are aware that a primary route for person-to-person transmission is through contact with bodily fluids from an infected person.

1 Jan 2025

Immunocompromised adults show weaker response to RSV vaccines

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity - primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of rejection and others with immune system disorders - do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with normal immune function.

30 Dec 2024